Stay updated on Nivolumab Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.

Latest updates to the Nivolumab Ibrutinib in CLL Clinical Trial page
- Check5 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoChange DetectedStudy status updated to Completed; results have been posted and enrollment and completion dates updated.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedThe change is a minor version update (v3.4.2 replacing v3.4.1) and does not affect study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedA new page revision, v3.4.1, was added and the previous revision v3.4.0 was removed; this appears to be a backend/UI version update rather than a change to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded a glossary toggle and site revision information (v3.4.0) along with the updated 'Last Update Submitted that Met QC Criteria' label. The previous wording 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and revision 'v3.3.4' were removed.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. There are no visible changes to the study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.